Tradestie Institutional Equity Comparison Engine

NUVB vs XERS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

XERS Overall Edge

XERS Captures Institutional Edge (4โ€“0 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xeris Biopharma Holdings, Inc. Common Stock (XERS) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NUVB trades at N/M Forward P/E with -61.2% operating margin (+242.6% YoY revenue) versus XERS at 63.6x Forward P/E and 12.7% operating margin (+44.2% YoY). In options structure, NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro) against XERS sits in SURGE (12th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner XERS
NUVB N/M vs XERS 63.6x Fwd P/E
Growth & Margin Winner XERS
Op Margin -61.2% vs 12.7% ยท YoY +242.6% vs +44.2%
Momentum & Technical Winner XERS
1Y -46.9% vs +139.3% ยท 52W Pos 2% vs 97%
Options & Structure Winner XERS
BREAKDOWN (26th %ile IV) vs SURGE (12th %ile IV)
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
1M Return -19.15%
1Y Return -46.85%
Forward P/E N/M
Unified AI Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
XERS NASDAQ
Xeris Biopharma Holdings, Inc. Common Stock
Pharmaceutical Preparations
$16.97
+2.11% 1D
Market Cap $3.0B
1M Return +56.26%
1Y Return +139.35%
Forward P/E 63.6x
Unified AI Score
35.7 / 100 SELL
Tech 50.0 Fund 34.0 Flow 71.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NUVB -46.85% XERS +139.35% Spread: +186.2 pp (XERS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period NUVB Revenue XERS Revenue NUVB Op. Margin XERS Op. Margin Margin Edge
FY2020 N/A $20M N/A -414.5% XERS
FY2021 N/A $50M N/A -232.2% XERS
FY2022 N/A $110M N/A -74.3% XERS
FY2023 N/A $160M N/A -26.8% XERS
FY2024 $10M $200M -7527.3% -16.6% XERS
FY2025 $60M $290M -338.7% 8.5% XERS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NUVB (3) vs XERS (7)
Institutional Metric NUVB XERS Criterion Row Winner
Market Capitalization Scale $1.3B $3.0B Larger Scale XERS
Trailing P/E Ratio Valuation N/M 87.0x Lower Multiple XERS
Forward P/E Ratio Valuation N/M 63.6x Lower Multiple XERS
Revenue Growth (YoY) Growth +242.6% +44.2% Higher Growth NUVB
Operating Margin (TTM) Profitability -61.2% 12.7% Higher Margin XERS
Net Profit Margin Profitability -67.4% -1.8% Higher Margin XERS
Return on Equity (ROE) Capital Efficiency -49.1% -27.1% Higher ROE XERS
52-Week Range Position Momentum 2% ($4โ€“$10) 97% ($5โ€“$17) Stronger Trend XERS
Beta / 30D Volatility Risk Regime 1.52ฮฒ ยท 55% Vol -0.04ฮฒ ยท 104% Vol Lower Realized Risk NUVB
Unified Institutional Score Composite Signal 61.0 / 100 (BUY) 35.7 / 100 (SELL) Higher Composite NUVB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NUVB vs XERS Buy Guide
NUVB BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 26th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live NUVB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
XERS SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live XERS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NUVB nor XERS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.